DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
(titres de publication, de périodique et noms de colloque inclus)
2006-04-01 - Article/Dans un journal avec peer-review - Anglais - 11 page(s)

Saussez Sven , Cucu Diana-Raluca, Decaestecker Christine, Chevalier Dominique, Kaltner Herbert, André Sabine, Wacrenier Agnès, Toubeau Gérard, Camby Isabelle, Gabius Hans-Joachim, Kiss Robert, "Galectin-7 (p53-Induced Gene-1): A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer" in Annals of Surgical Oncology, 13

  • Edition : Springer, New York (NY)
  • Codes CREF : Histologie (DI3212), Cancérologie (DI3349)
  • Unités de recherche UMONS : Anatomie et Biologie cellulaire (M112), Histologie (M118)
Texte intégral :

Abstract(s) :

(Anglais) Background Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate. We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration. Methods.The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3. Results High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1. Conclusions These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.

Identifiants :
  • PMID : 16788763
  • DOI : 10.1245/ASO.2006.08.033
  • ISSN : 1068-9265